Ovarian Histopathology in Breast Cancer Patients Receiving Tamoxifen

Kathryn F. McGonigle, K F McGonigle, S A Vasilev, Steven A. Vasilev, T Odom-Maryon, Tamara Odom‐Maryon, Jean F. Simpson, J F Simpson
Gynecologic oncology · 1999 · vol. 73(3) , pp. 402–406 · doi:10.1006/gyno.1999.5378 · PMID:10366467 · W2042400450
article OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This paper presents ovarian histopathology findings from breast cancer patients treated with tamoxifen.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Antineoplastic Agents, Hormonal Breast Neoplasms Ovary Ovary Tamoxifen Adult Aged Antineoplastic Agents, Hormonal Breast Neoplasms Female Humans Middle Aged Ovary Tamoxifen

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (22)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:29.640636+00:00
License: CC0 · commercial use OK